Comparison of 2002 TNM nodal status with lymph node density in node-positive patients after radical cystectomy for bladder cancer: Analysis by the number of lymph nodes removed

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 2, 2011, Pages 199-204

  Jeong, In Gab ^a   Park, Jinsung ^a   Song, Kanghyon ^a   Ro, Jae Y ^a   Song, Cheryn ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a Asan Medical Center   (South Korea)

Author keywords

Bladder neoplasm; Cystectomy; Lymph nodes; Prognosis

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE DENSITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 79952041485     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.04.006     Document Type: Article

References (21)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
2. Vieweg J., Gschwend J.E., Herr H.W., et al. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999, 161:449-454.
3. Frank I., Cheville J.C., Blute M.L., et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: Clinicopathologic features associated with outcome. Cancer 2003, 97:2425-2431.
4. Fleischmann A., Thalmann G.N., Markwalder R., et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005, 23:2358-2365.
5. Herr H.W. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003, 169:943-945.
6. Stein J.P., Cai J., Groshen S., et al. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: Concept of lymph node density. J Urol 2003, 170:35-41.
7. Kassouf W., Leibovici D., Munsell M.F., et al. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006, 176:53-57.
8. Kassouf W., Agarwal P.K., Herr H.W., et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: Analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008, 26:121-126.
9. Konety B.R., Joslyn S.A., O'Donnell M.A. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology, and End Results Program database. J Urol 2003, 169:946-950.
10. Wright J.L., Lin D.W., Porter M.P. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008, 112:2401-2408.
11. Jakse G., Algaba F., Fossa S., et al. EAU guidelines on bladder cancer. Muscle invasive and metastatic 2004.
12. Liedberg F., Månsson W. Lymph node metastasis in bladder cancer. Eur Urol 2006, 49:13-21.
13. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 10.1016/j.eururo. 2009.01.002.
14. Greene F.L., Page D.L., Fleming I.D., et al. Urinary bladder. AJCC Cancer Staging Manual 2002, 335-340. Springer, New York. 6th ed.
15. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
16. Herr H.W. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003, 61:105-108.
17. Leissner J., Hohenfellner R., Thüroff J.W., et al. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging, and prognosis. BJU Int 2000, 85:817-823.
18. Abdel-Latif M., Abol-Enein H., El-Baz M., et al. Nodal involvement in bladder cancer cases treated with radical cystectomy: Incidence and prognosis. J Urol 2004, 172:85-89.
19. Leissner J., Ghoneim H., Abol-Enein J., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multicenter study. J Urol 2004, 171:139-144.
20. Sanderson K.M., Stein J.P., Skinner D.G. The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urol Oncol 2004, 22:205-211.
21. Park J., Park S., Song C., et al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology 2007, 70:257-262.